首页> 外文期刊>Medical hypotheses >A possible 'universal' cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue.
【24h】

A possible 'universal' cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue.

机译:一种可能的“通用”癌症疫苗,可能引起针对源自任何组织的新兴癌细胞的免疫应答。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Since an ongoing interaction between a potential cancer cell and its microenvironment is a necessary requirement for their co-evolution towards a malignant disease state, a future success of cancer prevention will depend on how effectively a vaccination strategy simultaneously acts on emerging pretumor cells as well as on its microenvironment. Based on the assumption and theory that a placental vaccine could induce humoral and cell-mediated immune response against both the embryo-like antigens and angiogenic factors that are common to placental and cancer cells, this vaccination would create an immunological state in normal healthy individuals which would result in rejection of foreign nascent transforming cells, or cancer initiating cells (so called cancer stem cells). Immunoplacental Vaccine (Human placenta whole cell lysates) prepared upon Filatov's method, consisting of heat shock proteins and associated placental peptide complexes-version of homologous non-mutated proteins that are found on different kinds of epithelial cancer cells, when intradermal coinjected with an adjuvant, i.e. BCG-Vaccine, in normal healthy individuals, may function as a multi-epitope vaccine; the body recognizes the placental antigens of this vaccine as foreign, and thus stimulates a cross-reactive humoral and cell-mediated immune response targeting cancer tumor-associated antigens (TAA), as well as proteins that aid in cancer development. Also, by eliciting of critical cytokines at the vaccination site may result in cytokine-network balancing and in promoting Th1 cell-mediated immunity in the local microenvironment of preneoplastic to neoplastic transformation. Thus, this vaccination approach, by fine-tuning T-cell repertoire, T-cell regulation and cytokine-network balancing in the local microenvironment of preneoplastic to neoplastic transformation, acts on both "abnormal cells" and their "abnormal microenvironment", in which abnormal clones develop.
机译:由于潜在癌细胞与其微环境之间持续的相互作用是它们共同发展为恶性疾病状态的必要条件,因此,癌症预防的未来成功将取决于疫苗接种策略如何同时有效地作用于新出现的肿瘤前细胞以及在其微环境中。基于这样的假设和理论,胎盘疫苗可以诱导针对胎盘和癌细胞常见的胚胎样抗原和血管生成因子的体液和细胞介导的免疫反应,这种疫苗接种会在正常健康个体中产生免疫状态,会导致外来新生转化细胞或癌症起始细胞(所谓的癌症干细胞)被排斥。免疫胎盘疫苗(人胎盘全细胞裂解物)是根据Filatov的方法制备的,由热休克蛋白和相关的胎盘肽复合物组成,这些蛋白是在皮肤上与佐剂共注射时在不同种类的上皮癌细胞上发现的同源非突变蛋白,即,在正常健康个体中,BCG疫苗可作为多表位疫苗起作用;人体将这种疫苗的胎盘抗原识别为外源性抗原,从而刺激了针对癌症肿瘤相关抗原(TAA)以及有助于癌症发展的蛋白质的交叉反应性体液和细胞介导的免疫反应。同样,通过在疫苗接种部位引发关键细胞因子,可能导致细胞因子网络平衡,并在肿瘤前到肿瘤转化的局部微环境中促进Th1细胞介导的免疫。因此,这种疫苗接种方法通过微调T细胞库,T细胞调节和肿瘤前到肿瘤转化的局部微环境中的细胞因子网络平衡,对“异常细胞”及其“异常微环境”均起作用。异常克隆的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号